Upstream stimulatory factor regulates E box-dependent PAI-1 transcription in human epidermal keratinocytes

Journal of Cellular Physiology

Volumn 203, Issue 1, 2005, Pages 156-165

  Allen, Rosalie R ^a   Qi, Li ^a   Higgins, Paul J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; LUCIFERASE; MATRIGEL; OLIGODEOXYNUCLEOTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; UPSTREAM STIMULATORY FACTOR 1;

AMINO ACID SUBSTITUTION; ARTICLE; ATTENUATION; CELL MIGRATION; CELL MOTILITY; CHROMATIN; COMPLEX FORMATION; DNA FLANKING REGION; E BOX ELEMENT; ENZYME ACTIVITY; EPIDERMIS CELL; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE PROBE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KERATINOCYTE; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS;

BASE SEQUENCE; CELL LINE, TRANSFORMED; COLLAGEN; DRUG COMBINATIONS; EPIDERMIS; GENE EXPRESSION REGULATION; GENES, REPORTER; HELIX-LOOP-HELIX MOTIFS; HUMANS; KERATINOCYTES; LAMININ; LEUCINE ZIPPERS; LUCIFERASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS (GENETICS); PROTEOGLYCANS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 14744279743     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20211     Document Type: Article

References (76)

1. Akiyoshi S, Ishii M, Nemoto N, Kawabata M, Aburatani H, Miyazano K. 2001. Targets of transcriptional regulation by transforming growth factor-β: Expression profile analysis using oligonucleotide arrays. Jpn J Cancer Res 92:252-268.
2. Al-Fakhri N, Chavakis T, Schmidt-Woll T, Huang B, Cherian SM, Bobryshev YV, Lord RS, Katz N, Preissner KT. 2003. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol Chem 384:423-435.
3. Andreasen PA, Egelund R, Peterson HH. 2000. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25-40.
4. Arias AM. 2001. Epithelial mesenchymal interactions in cancer and development. Cell 105:425-431.
5. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM. 1998. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4:923-928.
6. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noel A. 2001. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152:777-784.
7. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. 2002. p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115:3193-3206.
8. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. 2001. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12:27-36.
9. Boehm JR, Kutz SM, Sage EH, Staiano-Coico L, Higgins PJ. 1999. Growth statedependent regulation of plasminogen activator inhibitor type-1 gene expression during epithelial cell stimulation by serum and transforming growth factor-β1. J Cell Physiol 181:96-106.
10. Brooks TD, Slomp J, Quax PHA, De Bart ACW, Spencer MT, Verheijen JH, Charlton PA. 2001. Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vivo. Clin Exp Metastasis 18:445-453.
11. Carter RS, Ordentlich P, Kadesch T. 1997. Selective utilization of basic helix-loop-helix-leucine zipper proteins at the immunoglobulin heavy-chain enhancer. Mol Cell Biol 17:18-23.
12. Chapman HA. 1997. Plasminogen activators, integrins, the coordinate regulation of cell adhesion and migration. Curr Opin Cell Biol 9:714-724.
13. Chappuis PO, Dieterich B, Sciretta V, Lohse C, Bonnefoi H, Remadi S, Sappino AP. 2001. Functional evaluation of plasmin formation in primary breast cancer. J Clin Oncol 19:2731-2738.
14. Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G. 2002. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer populations. Am J Path 160:237-246.
15. Cheung E, Mayr P, Coda-Zabetta F, Woodman PG, Boam DSW. 1999. DNA-binding activity of the transcription factor upstream stimulatory factor 1 (USF-1) is regulated by cyclin-dependent phosphorylation. Biochem J 344:145-152.
16. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. 2003. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160:781-791.
17. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. 1996. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134:1563-1571.
18. Deng G, Curriden SA, Hu G, Czekay R-P, Loskutoff DJ. 2001. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 189:23-33.
19. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. 1998. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17:3091-3100.
20. Dublin E, Hanby A, Patel NK, Liebman R, Barnes D. 2000. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong association with tumor pathology. Am J Pathol 157:1219-1227.
21. Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR. 1998. Transforming growth factor-β1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer 75:721-730.
22. Fink AR, Kazlauskas A, Poellinger L, Ebbesen P, Zachar V. 2002. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 99:2077-2083.
23. Galibert M-D, Carreira S, Goding CR. 2001. The Usf-1 transcription factor is a novel target for the stress-responsive p38 kinase and mediates UV-induced Tyrosinase expression. EMBO J 20:5022-5031.
24. Gilles C, Polette M, Birembaut P, Brunner N, Thompson EW. 1997. Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis 15:519-526.
25. Giusti C, Desruisseau S, Ma L, Calvo F, Martin P-M, Berthois Y. 2003. Transforming growth factor β-1 and amphiregulin act in synergy to increase the production of urokinase-type plasminogen activator in transformed breast epithelial cells. Int J Cancer 105:769-778.
26. Goodman RH, Smolik S. 2000. CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553-1577.
27. Goueli BS, Janknecht R. 2003. Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Oncogene 22:8042-8047.
28. Grinberg AV, Kerppola TK. 2003. Both Max and TFE3 cooperate with Smad proteins to bind the plasminogen activator inhibitor-1 promoter, but they have opposite effects on transcriptional activity. J Biol Chem 278:11227-11236.
29. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. 2000. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 60:5839-5847.
30. Hua X, Liu X, Ansari DO, Lodish HF. 1998. Synergistic cooperation of TFE3 and smad proteins in TGF-β-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev 12:3084-3095.
31. Hua X, Miller ZA, Wu G, Shi Y, Lodish HF. 1999. Specificity in transforming growth factor β-induced transcription of the plasminogen activator inhibitor-1 gene: Interactions of promoter DNA, transcription factor μE3, and Smad proteins. Proc Natl Acad Sci USA 96:13130-13135.
32. Ismail PM, Lu T, Sawadogo M. 1999. Loss of USF transcriptional activity in breast cancer cell lines. Oncogene 18:5582-5591.
33. Janknecht R. 2002. The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. Histol Histopathol 17:657-668.
34. Jeffers M, Rong S, Vande Woude GF. 1996. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16:1115-1125.
35. Johansson N, Ala-aho R, Uitto V, Grenman R, Fusenig NE, Lopez-Otin C, Kahari VM. 2000. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J Cell Sci 113:227-235.
36. Kietzmann T, Roth U, Jungermann K. 1999. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 94:4177-4185.
37. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossawski L, Andreasen PA. 1997. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 232:420-421.
38. Koziczak M, Krek W, Nagamine Y. 2000. Pocket protein-independent repression of urokinase-type plasminogen activator and plasminogen activator inhibitor 1 gene expression by E2F1. Mol Cell Biol 20:2014-2022.
39. Kutz SM, Hordines J, McKeown-Longo PJ, Higgins PJ. 2001. TGF-β1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci 114:3905-3914.
40. Lefrancois-Martinez AM, Martinez A, Antoine B, Raymondjean M, Kahn A. 1995. Upstream stimulatory factor proteins are major components of the glucose response complex of the L-type pyruvate kinase gene promoter. J Biol Chem 270:2640-2643.
41. Legrand C, Polette M, Tournier JM, de Bentzmann S, Huet E, Monteau M, Birembaut P. 2001. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial cell migration. Exp Cell Res 264:326-333.
42. Littlewood TD, Evan GI. 1995. Helox-loop-kelix proteins. Protein Profiles 2:612-703.
43. Liu G, Shuman MA, Cohen RL. 1995. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured ling cancer cells. Int J Cancer 60:501-506.
44. Loskutoff DJ, Curriden SA, Hu G, Deng G. 1999. Regulation of cell adhesion by PAI-1. APMIS 107:54-61.
45. Lund LR, Romer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, Stephens RW, Dano K. 1999. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 18:4645-4656.
46. Luo X, Sawadogo M. 1996. Functional domains of the transcription factor USF2: Atypical nuclear localization signals and context-dependent transcriptional activation domains. Mol Cell Biol 16:1367-1375.
47. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P. 1997. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. EMBO J 16:2319-2332.
48. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA. 2001. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276:33964-33968.
49. Meier JL, Luo X, Sawadogo M, Straus SE. 1994. The cellular transcription factor USF cooperates with varicella-zoster virus immediate-early protein 62 to symmetrically activate a bi-directional viral promoter. Mol Cell Biol 14:6896-6906.
50. Mignatti P, Rifkin DB. 2000. Nonenzymatic interactions between proteinases and the cell surface: Novel roles in normal and malignant cell physiology. Adv Cancer Res 78:103-157.
51. Okedon LE, Sato Y, Rifkin DB. 1992. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial migration independent of its proteolytic activity. J Cell Physiol 150:258-263.
52. Palmieri D, Lee JW, Juliano RL, Church FC. 2002. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-231 breast cancer cells. J Biol Chem 277:40950-40957.
53. Petzelbauer E, Springhorn JP, Tucker AM, Madri JA. 1996. Role of plasminogen activator inhibitor in the reciprocal regulation of bovine aortic endothelial and smooth muscle cell migration by TGF-β1. Am J Path 149:923-931.
54. Providence KM, Higgins PJ. 2004. PAI-1 expression is required for epithelial cell migration in two distinct phases of in vitro wound repair. J Cell Physiol 200:297-308.
55. Providence KM, Kutz SM, Staiano-Coico L, Higgins PJ. 2000. PAI-1 gene expression is regionally induced in wounded epithelial cell monolayers and required for injury repair. J Cell Physiol 182:269-280.
56. Providence KM, White LA, Tang J, Gonclaves J, Staiano-Coico L, Higgins PJ. 2002. Epithelial monolayer wounding stimulates binding of USF-1 to an E-box motif in the plasminogen activator inhibitor type 1 gene. J Cell Sci 115:3767-3777.
57. Providence KM, Staiano-Coico L, Higgins PJ. 2003. A quantifiable in vitro model to assess effects of PAI-1 gene targeting on epithelial motility. Methods Mol Med 78:293-303.
58. Qi L, Higgins PJ. 2003. Use of chromatin immunoprecipitation to identify E box-binding transcription factors in the promoter of the growth state-regulated human PAI-1 gene. Recent Res Devel Mol Biol 1:1-12.
59. Qyang Y, Luo X, Lu T, Ismail PM, Krylov D, Vinson C, Sawadogo M. 1999. Cell-type-dependent activity of the ubiquitous transcription factor USF in cellular proliferation and transcriptional activation. Mol Cell Biol 19:1508-1517.
60. Reijerkerk A, Voest EE, Gebbink MF. 2000. No grip, no growth: The conceptual basis of excessive proteolysis in the treatment of cancer. Eur J Cancer 36:1690-1705.
61. Riccio A, Pedone PV, Lund LR, Olsen T, Olsen HS, Andreasen PA. 1992. Transforming growth factor β1-responsive element: Closely associated binding sites for USF and CCAAT-binding transcription factor-nuclear factor 1 in the type-1 plasminogen activator inhibitor gene. Mol Cell Biol 12:1846-1855.
62. Ryan MP, Kutz SM, Higgins PJ. 1996. Complex regulation of plasminogen activator inhibitor type-1 (PAI-1) gene expression by serum and substrate adhesion. Biochem J 314:1041-1046.
63. Samoylenko A, Roth U, Jungermann K, Kietzmann T. 2001. The upstream stimulatory factor-2a inhibits plasminogen activator inhibitor-1 gene expression by binding to a promoter element adjacent to the hypoxia-inducible factor-1 binding site. Blood 97:2657-2666.
64. Santibanez JF, Frontelo P, Iglesias M, Martinez J, Quintanilla M. 1999. Urokinase expression and binding activity associated with the transforming growth factor β1-induced migratory and invasive phenotype of mouse epidermal keratinocytes. J Cell Biochem 74:61-73.
65. Sirito M, Lin Q, Deng JM, Behringer RR, Sawadogo M. 1998. Overlapping roles and asymmetrical cross-regulation of the USF proteins in mice. Proc Natl Acad Sci USA 95:3758-3763.
66. Stefansson S, Lawrence DA. 2003. Old dogs and new tricks: Proteases, inhibitors, and cell migration. Sci STKE 189:pe24.
67. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. 2001. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276:8135-8141.
68. Szentirmay MN, Yang HX, Pawar SA, Vinson C, Sawadogo M. 2003. The IGF2 receptor is a USF2-specific target in nontumorigenic mammary epithelial cells but not in breast cancer cells. J Biol Chem 278:37231-37240.
69. Thiery JP. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454.
70. Viollet B, Lefrancois-Martinez AM, Henrion A, Kahn A, Raymondjean M, Martinez A. 1996. Immunochemical characterization and transacting properties of upstream stimulatory factor isoforms. J Biol Chem 271:1405-1415.
71. Weilbaecher KN, Motyckova G, Huber WE, Takemoto CM, Hemesath TJ, Xu Y, Hershey CL, Dowland NR, Wells AG, Fisher DE. 2001. Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice. Mol Cell 8:749-758.
72. White LA, Bruzdzinski C, Kutz SM, Gelehrter TD, Higgins PJ. 2000. Growth state-dependent binding of USF-1 to a proximal promoter E box element in the rat plasminogen activator inhibitor type 1 gene. Exp Cell Res 260:127-135.
73. Xing W, Danilovich N, Sairam MR. 2002. Orphan receptor chicken ovalbumin upstream promoter transcription factors inhibit steroid factor-1, upstream stimulatory factor, and activator protein-1 activation of ovine follicle-stimulating hormone receptor expression via composite cis-elements. Biol Reprod 66:1656-1666.
74. Yu L, Herbert MC, Zhang YE. 2002. TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J 21:3749-3759.
75. Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, Piek E, Bottinger EP. 2001. Genetic programs of epithelial cell plasticity directed by transforming growth factor-β. Proc Natl Acad Sci USA 98:6686-6691.
76. Zhou HM, Nichols A, Meda P, Vassalli JD. 2000. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 19:4817-4826.